Free tool
FAERS Monitor: Pombiliti
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761204 or its brand name (Pombiliti, Cipaglucosidase Alfa-Atga). Reports on generic versions are filed under their own applications.
Reports
91
Serious
47
52% of reports
Hospitalization
19
Death reported
9
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue10
- nausea10
- asthenia7
- product dose omission issue7
- vomiting7
- malaise6
- death5
- dyspnoea5
- headache5
- hypertension5
- infusion related reaction5
- pneumonia5
- abdominal discomfort4
- abdominal pain upper4
- dizziness4
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 28 |
| 2025 | 30 |
| 2026 | 33 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,068 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| infusion related reactionSignal | 5 | 17.4 | 7.4 | 62 |
| abdominal discomfortSignal | 4 | 5.5 | 2.1 | 11 |
| product dose omission issueSignal | 7 | 5.5 | 2.7 | 22 |
| hypertensionSignal | 5 | 5.5 | 2.3 | 14 |
| abdominal pain upperSignal | 4 | 4.5 | 1.7 | 8 |
| astheniaSignal | 7 | 4.3 | 2.1 | 15 |
| pneumoniaSignal | 5 | 3.6 | 1.5 | 7 |
| vomitingSignal | 7 | 3.4 | 1.7 | 10 |
| malaiseSignal | 6 | 3.2 | 1.5 | 7 |
| fatigueSignal | 10 | 3.0 | 1.7 | 12 |
| nauseaSignal | 10 | 2.9 | 1.6 | 11 |
| dyspnoea | 5 | 2.0 | 0.9 | 2 |
| dizziness | 4 | 1.9 | 0.7 | 1 |
| headache | 5 | 1.8 | 0.8 | 1 |
| death | 5 | 1.3 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.